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TP53 is a tumor suppressor gene that encodes the protein 
p53, which is involved in cell cycle arrest in damaged cells that 
require DNA repair or in cases of damage beyond repair, trig-
gering apoptosis. A defect in TP53 is a crucial step in carcino-
genesis. Previous studies noted that either a defect of the TP53 
gene itself or of a gene upstream or downstream of TP53 was 
found in virtually all human cancers [1-3]. In gastric cancer (GC), 
p53 overexpression has been reported in 37.8%–54% of cases 
[4-6]. According to those studies, overexpression of p53 was 
generally associated with worse overall survival (OS) as well as 
well-known prognostic factors such as vascular invasion and 
lymph node metastasis.
In 2014, The Cancer Genome Atlas (TCGA) Research Net-
work Group proposed a molecular classification of GC [6]. The 
four subgroups were Epstein-Barr virus (EBV)–positive, micro-
satellite instability, genomic stability, and chromosomal insta-
bility. TP53 alteration is a characteristic of the chromosomal 
instability group. In the following year, the Asian Cancer Research 
Group (ACRG) presented a different molecular classification 
that considered the three factors of microsatellite instability, ep-
ithelial-mesenchymal transition, and TP53 mutation [7]. The 
four groups classified by those factors exhibited different prog-
noses. However, one of the limitations of those two studies was 
that the methodology used requires high-end and high-cost 
technologies such as next-generation gene sequencing. Differ-
ent groups have attempted to develop a more practical imple-
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mentation of the molecular classification of GC in clinical set-
tings based on the biomarkers of TCGA and ACRG studies [8-10]. 
The immunohistochemistry (IHC) of p53 was used to practi-
cally predict the mutation status of TP53, but interpretation of 
p53 IHC was varied and has yet to be confirmed. Köbel et al. 
[11] demonstrated that optimal p53 IHC can accurately predict 
the mutation status of TP53 in ovarian cancer, which can be very 
useful in diagnosis of high-grade serous carcinoma. This tech-
nique has yet to be validated for GC. 
In this study, we aimed to measure the sensitivity, specificity, 
and accuracy of p53 IHC as a representation of TP53 mutation 
status and to investigate the correlation between clinicopatho-
logic features and p53 IHC or TP53 mutations in GC. There-
fore, we performed next-generation sequencing (NGS) and p53 
IHC in 120 GC cases, and the TP53 mutation statuses were 
compared with the p53 IHC results. 
MATERIALS AND METHODS
Characterization of patients and sample acquisition
The study population was composed of 120 patients treated 
at Seoul National University Bundang Hospital (Seongnam, 
Korea) from 2009 to 2019. The median age was 60 years (range, 
34 to 82 years), and 85 patients (70.8%) were men. Thirty-eight 
of the 120 cases (31.7%) were stage II at initial diagnosis, 71 
(59.2%) cases were stage III, and 11 (9.2%) were stage IV. 
Among them, 109 stage II and III patients (90.8%) underwent 
curative radical resection (R0 resection) without preoperative 
chemotherapy or radiotherapy. In the 11 stage IV cases, endo-
scopic biopsy specimen was collected in one case, metastatectomy 
specimens in four cases, conversion surgery specimens after che-
motherapy in five patients, and gastrectomy specimen in one case 
for the experiments. Analysis according to the World Health 
Organization (WHO) classification [12] revealed that tubular 
adenocarcinoma accounted for 54.2% (65 cases) of diagnoses, 
mucinous adenocarcinoma for 3.3% (4 cases), papillary adeno-
carcinoma for 3.3% (4 cases), poorly cohesive carcinoma for 
30.0% (36 cases), and other minor histologic types for 9.2% (11 
cases). For survival analysis, 109 patients with stage II and III 
GC were followed up from the date of surgery to the date of 
death or final follow-up. The median follow-up period was 42.2 
months (range of 5.4-87.7 months).
Next-generation sequencing
Targeted sequencing of 170 cancer-related gene panels was 
performed using formalin-fixed, paraffin-embedded tissue (FFPE) 
samples as previously described [13]. All FFPE materials had a 
short cold ischemic time not exceeding 2 hours, fixation time 
ranging from 8 to 72 hours, and were aged between 0 and 9 years.
In brief, approximately 3 µg of genomic DNA was extracted 
from FFPE tumor tissues, and the sequencing library was pre-
pared using an Agilent SureSelect Target Enrichment Kit (Agi-
lent Technologies, Santa Clara, CA, USA) following the manu-
facturer’s guidelines. High-throughput sequencing was performed 
using the HiSeq 2500 system (Illumina, San Diego, CA, USA) 
(Macrogen Inc., Seoul, Korea). After quality control of the 
FASTQ files, sequencing reads were aligned to the reference ge-
nome (GRCh37/hg19) using Burrows-Wheeler Aligner-MEM 
(BWA-MEM) [14]. Single nucleotide variants and small inser-
tions and deletions (INDELs) were detected using the MuTect2 
algorithm [15]. SnpEff and SnpSift v4.3i [16] with dbNSFP 
v2.9.3 [17] were used for variant annotation with various data-
bases including the OncoKB [18] and ClinVar archives [19].
IHC staining
Immunohistochemical (IHC) staining for p53 (DO7, mouse 
monoclonal, Dako, Agilent Technologies) was performed on 
3-μm-thick slides using an automated immunostainer (Bench-
Mark XT, Ventana Medical Systems, Tucson, AZ, USA) follow-
ing the manufacturer’s protocol. The p53 IHC was interpreted 
in three tiers: strong nuclear staining in more than 10% of the 
tumor cells was considered strong positivity, samples without 
any nuclear staining of tumor cells (complete absence) were in-
terpreted as negativity, and cases exhibiting weak, scattered, or 
patchy positivity were regarded as weak positivity. Representa-
tive images for each category are shown in Fig. 1. Cut-offs of 
20% and 30% nuclear positivity were additionally applied for 
validation of the results.
For cases where gene mutation and protein expression status 
did not match (18 cases or 15.0%), p53 IHC was repeatedly per-
formed and interpreted. In most cases (17 out of 18 or 94.4%), 
repeated immunohistochemical assays did not alter the initial 
interpretation. Tumor heterogeneity accounted for the change in 
one case. Initially, strong nuclear expression of p53 was observed 
in some areas of the tumor (< 10%) but was not sufficient to be 
classified as strong expression. Subsequent IHC was performed 
on another section of the same tumor, exhibiting overall strong 
expression of p53. 
EBV in-situ hybridization
The EBV status was tested using EBV in-situ hybridization 
as previously described [20]. A fluorescein-conjugated EBV en-
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coded small RNA (EBER) oligonucleotide probe (INFORM 
EBVencoded RNA probe, Ventana Medical Systems) was used, 
and positive cases were defined as diffuse nuclear reactivity for 
EBER in tumor cells.
Microsatellite instability analysis
Representative tumor tissues and matched normal gastric 
mucosal tissues were selected for microsatellite instability (MSI) 
testing. Five NCI markers (BAT-26, BAT-25, D5S346, D17S250, 
and S2S123) amplified through polymerase chain reaction were 
analyzed using an automated sequencer (ABI 3731 Genetic An-
alyzer; Applied Biosystems, Foster City, CA, USA). MSI-high 
was defined as two or more markers with unstable peaks, MSI-low 
was defined as one unstable marker, and microsatellite stable was 
defined as no unstable marker.
Statistical analyses 
Chi-square or Fisher exact tests were used to assess significant 
differences in the distribution of TP53 mutations and p53 ex-
pression. For univariate survival analysis, Kaplan-Meier survival 
curves were plotted in 109 patients with stage II and III GC 
cases. The survival differences were compared using the log-rank 
test. For multivariate survival analysis, the Cox regression model 
was used. All statistical analyses were performed using SPSS Sta-
tistics ver. 22.0 (IBM Corp., Armonk, NY, USA). 
RESULTS
Gene mutation and protein expression correlation
Table 1 summarizes the p53 IHC results according to TP53 
mutations. TP53 mutations were present in 52 cases (43.3%), 
of which missense mutations were the most common (33 of 52 
cases, 63.5%). Strong expression was observed in 34 cases (28.3%) 
and negative expression was observed in 27 cases (22.5%). When 
TP53 mutations were compared with p53 IHC, 30 of the 33 
missense mutation cases (90.9%) exhibited strong p53 expres-
sion, but negative expression of p53 was the dominant pattern 
(15 cases, 78.9%) among the 19 cases of other types of muta-
tions (p < .001). Based on clinical significance, 37 cases (30.1%) 
had pathogenic or likely pathogenic TP53 mutations, of which 
22 cases (59.5%) exhibited strong expression of p53, 13 cases 
(36.1%) negative expression, and two cases (5.4%) weak ex-
Table 1. Comparison between TP53 genetic mutations and p53 
immunohistochemistry
TP53 mutation




Mutation status < .001
Wild-type 1 (2.9) 12 (44.4) 55 (93.2) 68 (56.7)
Mutation present 33 (97.1) 15 (55.6) 4 (6.8) 52 (43.3)
Variant summary < .001
Wild-type 1 (2.9) 12 (44.4) 55 (93.2) 68 (56.7)
Missense 30 (88.2) 0 3 (5.1) 33 (27.5)
Other 3 (8.9) 15 (55.6) 1 (1.7) 19 (15.8)
Stop-gained 2 (5.9) 3 (11.1) 1 (1.7) 6 (5.0)
Splice region 0 5 (18.5) 0  5 (4.2)
Frameshift 0 7 (25.9) 0  7 (5.8)
In-frame deletion 1 (2.9) 0   0  1 (0.8)
Clinical significancea < .001
Wild-type 1 (2.9) 12 (44.4) 55 (93.2) 68 (56.7)
Pathogenic or likely 
  pathogenic
22 (64.7) 13 (48.1) 2 (3.4) 37 (30.1)
Uncertain significance 5 (14.7) 2 (7.4) 1 (1.7) 8 (6.7)
Conflicting 
  interpretation
6 (17.6) 0   1 (1.7) 7 (5.8)
Total 34 27 59 120
Values are presented as number (%).
aAccording to the ClinVar and OncoKB databases accessed on March 18, 
2020.  
Fig. 1. Representative images of strong expression (A), weak expression (B), and loss of expression (C). 
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pression (p < .001). Nevertheless, most cases of uncertain signif-
icance (62.5%) and conflicting interpretations (85.7%) also 
showed strong expression of p53 by IHC. 
Detailed information about TP53 mutations and p53 expres-
sion status is shown in Table 2. Two mutations were observed in 
three cases, of which one representative mutation was included 
in this table. One among seven cases with TP53 mutations of 
conflicting interpretations regarding pathogenicity had weak 
expression of p53 (case No. 27 in Table 2). There have been reports 
suggestive of the “likely benign” and “uncertain significance” 
nature of this mutation. The mutations c.659A > G, c.742C > T, 
c.817C > T, c.796G > A, c.1024C > T, and c.375G > A were 
found in two cases, and c.818G > A mutation was found in three 
cases. The IHC results matched in cases with the same muta-
tion. In 44 cases with single nucleotide polymorphism, C:G to 
T:A conversion was observed in 32 (72.7%), C:G to A:T in four 
(9.1%), C:G to G:C in two (4.5%), T:A to C:G in four (9.1%), 
and T:A to G:C in two (4.5%). 
Sensitivity, specificity, and accuracy of p53 IHC for predict-
ing TP53 mutations
In general, nonsynonymous mutations detected using NGS 
were related to strong p53 expression in IHC. Similarly, all other 
types of mutations tended to show negative expression, of p53 
while cases with wild-type TP53 exhibited weak protein expres-
sion. The sensitivity of strong expression of p53 by IHC for 
predicting nonsynonymous TP53 mutations was 90.9%, sensi-
tivity of negative expression for other types of mutations was 
79.0%, and the sensitivity of weak expression for wild-type 
TP53 was 80.9% (Table 3). The specificity for each category was 
95.4%, 88.1%, and 92.3%, respectively. The accuracy for each 
category was 94.2%, 86.7%, and 85.8%, respectively. In addi-
tion, the sensitivity, specificity, and accuracy of p53 IHC at 20% 
and 30% cut-offs are shown in Supplementary Table S1. The 
sensitivity of strong expression of p53 for nonsynonymous TP53 
mutations was highest at the 10% cut-off.
Clinicopathological variables and protein expression 
correlations
The correlation between clinicopathological characteristics 
and TP53 mutations or p53 expression status is summarized in 
Table 4. TNM stage at initial diagnosis was the only variable 
that showed significant correlation with both TP53 mutation 
type and p53 expression status (p = .004 and p = .029, respec-
tively). Of the 38 stage II gastric cancer cases, 27 (71.1%) did 
not exhibit any detectable mutations in the TP53 gene, but five 
nonsynonymous (13.2%) and six other types of mutations (15.8%) 
were found. Strong p53 expression was found in seven of the 38 
stage II cases (18.4%). Among the stage III cases, which accounted 
for 71 cases, the proportions of nonsynonymous gene mutations 
and strong expression of p53 mutations increased to 39.4% (28 
cases) and 38.0% (27 cases), respectively. On the other hand, 
the proportions of wild-type TP53 cases and weak expression 
cases decreased from 71.0% to 45.0% and from 55.2% to 
43.6%, respectively. 
TP53 mutations were more frequently observed in intestinal-
type GC (25 of 45 cases, 55.6%) compared to the non-intestinal 
type (27 of 75 cases, 36.0%), but with borderline statistical sig-
nificance (p = .065). Other clinicopathological variables such as 
sex, age, tumor location, and WHO classification were not sta-
tistically significant.
Survival analysis
One hundred nine patients with stage II and III GC at initial 
diagnosis were selected for survival analysis. The patients under-
went curative surgery followed by adjuvant chemotherapy. Patients 
with any TP53 mutations tended to have worse OS compared to 
those without mutations, although the difference was not statis-
tically significant (p = .227). When OS was analyzed based on 
TP53 mutation type, patients with nonsynonymous mutations 
had the worst OS, and the wild-type and other types of muta-
tions exhibited similar OS (p = .074) (Fig. 2A). This trend be-
came statistically significant when the nonsynonymous muta-
tion group was compared to the combined wild-type and other 
mutation groups (p = .028) (Fig. 2B). The expression pattern of 
p53 was not significantly associated with patient OS (p = .107) 
(Fig. 2C), but it was statistically significant when strong expres-
sion of p53 was compared to the combined negative and weak 
expression cases (p = .035) (Fig. 2D). Patients with abnormal—
negative and strong expression—expression did not exhibit a 
statistically significant survival difference compared to patients 
with weak expression (p = .208). The Kaplan-Meier survival 
curves of p53 expression status at 20% and 30% cut-offs were 
additionally plotted in Supplementary Fig. S1. The difference 
in survival was largest at the 30% cut-off. Multivariate Cox re-
gression analysis showed that strong expression of p53 was as-
sociated with patient OS independent of stage with borderline 
significance (p = .070, data not shown). The presence of nonsyn-
onymous missense mutations of TP53 was not an independent 
prognostic factor in multivariate analysis (p = .130).
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Table 2. Detailed information of TP53 mutation and p53 expression status in gastric cancer patients with any TP53 mutation
Case 
No.
Effect Nucleic acid alteration Amino acid alteration Clinical significancea
1 Missense_variant c.422G > A p.Cys141Tyr Pathogenic or likely pathogenic
2 Missense_variant c.422G > T p.Cys141Phe Pathogenic or likely pathogenic
3 Missense_variant c.455C > T p.Pro152Leu Pathogenic or likely pathogenic
4 Missense_variant c.524G > A p.Arg175His Pathogenic or likely pathogenic
5 Missense_variant c.535C > G p.His179Asp Pathogenic or likely pathogenic
6 Missense_variant c.542G > A p.Arg181His Pathogenic or likely pathogenic
7 Missense_variant c.659A > G p.Tyr220Cys Pathogenic or likely pathogenic
8 Missense_variant c.659A > G p.Tyr220Cys Pathogenic or likely pathogenic
9 Missense_variant c.701A > G p.Tyr234Cys Pathogenic or likely pathogenic
10 Missense_variant c.725G > A p.Cys242Tyr Pathogenic or likely pathogenic
11 Missense_variant c.734G > A p.Gly245Asp Pathogenic or likely pathogenic
12 Missense_variant c.742C > T p.Arg248Trp Pathogenic or likely pathogenic
13 Missense_variant c.742C > T p.Arg248Trp Pathogenic or likely pathogenic
14 Missense_variant c.743G > A p.Arg248Gln Pathogenic or likely pathogenic
15 Missense_variant c.772G > A p.Glu258Lys Pathogenic or likely pathogenic
16 Missense_variant c.817C > T p.Arg273Cys Pathogenic or likely pathogenic
17 Missense_variant c.817C > T p.Arg273Cys Pathogenic or likely pathogenic
18 Missense_variant c.818G > A p.Arg273His Pathogenic or likely pathogenic
19 Missense_variant c.818G > A p.Arg273His Pathogenic or likely pathogenic
20 Missense_variant c.818G > A p.Arg273His Pathogenic or likely pathogenic
21 Missense_variant c.380C > T p.Ser127Phe Conflicting interpretations of pathogenicity
22 Missense_variant c.473G > C p.Arg158Pro Conflicting interpretations of pathogenicity
23 Missense_variant c.481G > A p.Ala161Thr Conflicting interpretations of pathogenicity
24 Missense_variant c.613T > C p.Tyr205His Conflicting interpretations of pathogenicity
25 Missense_variant c.796G > A p.Gly266Arg Conflicting interpretations of pathogenicity
26 Missense_variant c.796G > A p.Gly266Arg Conflicting interpretations of pathogenicity
27 Missense_variant c.1015G > A p.Glu339Lys Conflicting interpretations of pathogenicity
28 Missense_variant c.329G > A p.Arg110His Uncertain significance
29 Missense_variant c.380C > A p.Ser127Tyr Uncertain significance
30 Missense_variant c.476C > T p.Ala159Val Uncertain significance
31 Missense_variant c.797G > T p.Gly266Val Uncertain significance
32 Missense_variant c.400T > G p.Phe134Val Uncertain significance
33 Missense_variant c.470T > G p.Val157Gly Uncertain significance
34 Frameshift_variant c.331_332insAG p.Leu111fs Pathogenic or likely pathogenic
35 Frameshift_variant c.381_391delCCCTGCCCTCA p.Pro128fs Pathogenic or likely pathogenic
36 Frameshift_variant c.635_669delTTCGACATAGTGTGGTG 
  GTGCCCTATGAGCCGCCT
p.Phe212fs Pathogenic or likely pathogenic
37 Frameshift_variant c.660_661delTG p.Tyr220fs Pathogenic or likely pathogenic
38 Frameshift_variant c.747delG p.Arg249fs Pathogenic or likely pathogenic
39 Frameshift_variant c.1169delC p.Pro390fs Pathogenic or likely pathogenic
40 Frameshift_variant c.778_779delTC p.Ser260fs Uncertain significance
41 Conservative_inframe_deletion c.529_546delCCCCACCATGAGCGCTGC p.Pro177_Cys182del Pathogenic or likely pathogenic
42 Stop_gained c.159G > A p.Trp53* Pathogenic or likely pathogenic
43 Stop_gained c.437G > A p.Trp146* Pathogenic or likely pathogenic
44 Stop_gained c.586C > T p.Arg196* Pathogenic or likely pathogenic
45 Stop_gained c.637C > T p.Arg213* Pathogenic or likely pathogenic
46 Stop_gained c.1024C > T p.Arg342* Pathogenic or likely pathogenic
47 Stop_gained c.1024C > T p.Arg342* Pathogenic or likely pathogenic
48 Splice_region_variant&synonymous_variant c.375G > A p.Thr125Thr Pathogenic or likely pathogenic
49 Splice_region_variant&synonymous_variant c.375G > A p.Thr125Thr Pathogenic or likely pathogenic
50 Splice_region_variant&synonymous_variant c.375G > C p.Thr125Thr Pathogenic or likely pathogenic
51 Splice_acceptor_variant&intron_variant c.920 - 1G > A Pathogenic or likely pathogenic
52 Splice_donor_variant&intron_variant c.96 + 1G > A Uncertain significance (no report)
IHC, immunohistochemistry.
aAccording to the ClinVar and OncoKB databases accessed on March 18, 2020.
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DISCUSSION
TP53 is the most well-known tumor suppressor gene, and 
p53 IHC is a method used in daily practice as a surrogate marker 
in various cancer patients. In this study, we performed targeted 
deep sequencing for detecting various TP53 mutations and 
IHC for p53 using a commercially available and validated primary 
antibody with an automatic immunostainer. Strong expression 
of p53 could predict nonsynonymous missense mutations of 
TP53 with a sensitivity of 90.9%, specificity of 95.4%, and accu-
racy of 94.2%. However, weak expression of p53 was less spe-
cific (80.9%) for predicting wild-type TP53, and negative expres-
sion was less sensitive (79.0%) for predicting other mutations of 
TP53. These results suggest that p53 IHC can be used as a sur-
rogate marker in predicting TP53 mutations, especially for 
strong expression, to predict nonsynonymous mutations. There 
Table 4. Clinicopathologic characteristics according to TP53 mutation and p53 expression status 
Characteristic Total
TP53 mutation p53 expression
NS Other Wild p-value Strong Negative Weak p-value
No. 120 33 19 68 34 27 59
Age (yr) 0.248 0.470
< 65 69 (57.5) 15 (45.5) 11 (57.9) 43 (63.2) 17 (50.0) 15 (55.6) 37 (62.7)
≥ 65 51 (42.5) 18 (54.5) 8 (42.1) 25 (36.8) 17 (50.0) 12 (44.4) 22 (37.3)
Sex 0.117 0.285
Male 85 (70.8) 27 (81.8) 15 (78.9) 43 (63.2) 27 (79.4) 20 (74.1) 38 (64.4)
Female 35 (29.2) 6 (18.2) 4 (21.1) 25 (36.8) 7 (20.6) 7 (25.9) 21 (35.6)
Location of tumor center 0.940 0.856
Lower third 53 (44.2) 15 (45.5) 10 (52.6) 28 (41.2) 16 (47.1) 11 (40.7) 26 (44.1)
Middle third 33 (27.5) 9 (27.3) 4 (21.1) 20 (29.4) 7 (20.6) 8 (29.6) 18 (30.5)
Upper third 34 (28.3) 9 (27.3) 5 (26.3) 20 (29.4) 11 (32.4) 8 (29.6) 15 (25.4)
TNM at initial diagnosis 0.004 0.029
II 38 (31.7) 5 (15.2) 6 (31.6) 27 (39.7) 7 (20.6) 10 (37.0) 21 (35.6)
III 71 (59.2) 28 (84.8) 11 (57.9) 32 (47.1) 27 (79.4) 13 (48.1) 31 (52.5)
IV 11 (9.2) 0 � 2 (10.5) 9 (13.2) 0 � 4 (14.8) 7 (11.9)
WHO classification 0.733 0.596
Papillary 4 (3.3) 1 (3.0) 1 (5.3) 2 (2.9) 1 (2.9) 2 (7.4) 1 (1.7)
Tubular WD/MD 28 (23.3) 10 (30.3) 6 (31.6) 12 (17.6) 10 (29.4) 6 (22.2) 12 (20.3)
Tubular PD 37 (30.8) 9 (27.3) 7 (36.8) 21 (30.9) 10 (29.4) 8 (29.6) 19 (32.2)
PCC 36 (30.0) 8 (24.2) 3 (15.8) 25 (36.8) 7 (20.6) 7 (25.6) 22 (37.3)
Mucinous 4 (3.3) 2 (6.1) 0 � 2 (2.9) 2 (5.9) 1 (3.7) 1 (1.7)
Others 11 (9.2) 3 (9.1) 2 (10.5) 6 (8.8) 4 (11.7) 3 (11.1) 4 (6.8)
Lauren classification 0.065 0.587
Intestinal 45 (37.5) 14 (42.4) 11 (57.9) 20 (29.4) 15 (44.1) 10 (37.0) 20 (33.9)
Non-intestinal 75 (62.5) 19 (57.6) 8 (42.1) 48 (70.6) 19 (55.9) 17 (63.0) 39 (66.1)
EBV 0.215 0.036
Negative 105 (87.5) 31 (93.9) 18 (94.7) 56 (82.4) 30 (88.2) 27 (100) 48 (81.4)
Positive 15 (12.5) 2 (6.1) 1 (5.3) 12 (17.6) 4 (11.8) 0 � 11 (18.6)
MSI 0.258 0.010
MSS/MSI-L 112 (93.3) 32 (97.0) 19 (100) 61 (89.7) 34 (100) 27 (100) 51 (86.4)
MSI-H 8 (6.7) 1 (3.0) 0 � 7 (10.3) 0 � 0 � 8 (13.6)
Values are presented as number (%).
NS, nonsynonymous; Other, other type mutation; wild, wild-type; WHO, World Health Organization; WD, well-differentiated; MD, moderately differentiated; 
PD, poorly differentiated; PCC, poorly cohesive carcinoma; EBV, Epstein-Barr virus; MSI, microsatellite instability; MSS, microsatellite stable; MSI-L, microsat-
ellite instability-low; MSI-H, microsatellite instability-high. 
Table 3. The sensitivity, specificity, and accuracy of p53 immunohistochemistry for predicting TP53 mutation, cut-off 10%
TP53 mutation Sensitivity (%) Specificity (%) Accuracy (%)
Nonsynonymous mutation by p53 strong expression 90.9 95.4 94.2
Other type mutation by negative expression of p53 79.0 88.1 86.7
Wild-type by weak expression of p53 80.9 92.3 85.8
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have been recent attempts to use IHC for molecular classifica-
tions, and their clinicopathological significance has been increas-
ingly important in GC [8,10]. Our results will be helpful for 
these new molecular classifications although negative expres-
sion should be cautiously interpreted.
Based on the Kaplan-Meier survival analysis, strong expres-
sion of p53 was significantly associated with worse OS compared 
to weak and negative expression of p53 in this study. Previous 
studies that investigated any relationship between p53 overex-
pression and survival reported p53 overexpression as a poor prog-
nostic factor [21-23], similar to the findings from our study. Some 
studies did not reveal the prognostic significance of p53 overex-
pression in GC, but a meta-analysis demonstrated that it is a 
poor prognostic factor [24]. In those studies, the median cut-off 
value was 10% [24]. Therefore, we applied a cut-off value of 10% 
for defining strong expression of p53. In addition to the 10% cut-
off, we applied 20% and 30% cut-offs in this study. Although 
the survival difference was largest at the 30% cut-off, the sensi-
tivity of strong expression of p53 for predicting nonsynony-
mous TP53 mutation was highest at the 10% cut-off. There-
fore, further studies are needed to validate various cut-offs. 
For interpretation of p53 IHC, Köbel et al. [11,25] proposed 
a three-tiered scoring system, including overexpression, complete 
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Fig. 2 . Kaplan-Meier survival curves of cumulative survival rate versus follow-up months after surgery according to mutation status (A, B) 
and immunohistochemistry results (C, D). (A) Nonsynonymous mutations (NS, beige) versus wild-type (WT, green) versus other types of mu-
tations (other, green) (p = .074). (B) Nonsynonymous mutations (NS, green) versus combined wild-type and other types of mutations (other, 
blue) (p = .028). (C) Strong (beige) versus weak (green) versus negative expression (Neg) (p =. 107). (D) Strong (green) versus combined weak 
and negative expression (Neg + Weak, blue) (p = .035). 
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scoring system exhibited good correlation with TP53 mutation 
status: overexpression with nonsynonymous mutation; com-
plete absence with stop gain, frameshift, and splicing muta-
tions; and a normal pattern with the wild-type TP53 gene [11]. 
Shin et al. [26] investigated the prognostic roles of p53 expres-
sion status in patients with GC. They defined group 0 as com-
plete absence, group 1 as weak staining in < 50%, group 2 as 
strong staining in 50%–90%, and group 3 as strong staining in 
> 90%. When the Kaplan-Meier survival analysis was performed, 
group 1 was associated with better survival than groups 0, 2, 
and 3, but with borderline statistical significance. Our results 
showed a similar relationship between p53 IHC and TP53 mu-
tation status to those of previous studies. If weak expression in 
this study was defined as a normal or wild-type pattern, the Ka-
plan-Meier survival curves did not show a significant difference 
between normal and abnormal expression patterns. Further-
more, patients with GC having nonsynonymous TP53 muta-
tions had significantly worse prognosis compared to patients 
with other types of mutations and the wild-type TP53 group. 
Similarly, strong expression of p53, which was related to non-
synonymous TP53 mutations, was shown to be a poor prognostic 
factor. The complete absence of p53 expression or other types of 
TP53 mutations might not be significant for predicting prog-
nosis. 
There were 17 cases (14.2%) with discrepant results between 
p53 IHC and TP53 mutations. Most discrepant cases had nega-
tive expression of p53 and wild-type TP53. Weak expression of 
p53 was observed in four missense mutation cases and one stop 
gain mutation case. These findings might be due to tumor het-
erogeneity or tissue quality issues, such as specimen ischemic time 
or archival age. In addition, there was one case with weak p53 
expression and a missense mutation of conflicting pathogenic 
interpretation. Considering this case was conflicting between 
uncertain significance and likely benign significance, one of the 
possible reasons for the discrepancy is a non-pathogenic muta-
tion. To discriminate functional and nonfunctional p53, Nenutil 
et al. [27] performed IHC for p53, Ki67, MDM2, and p21 in 
human cancers, and overexpressed p53 without increased MDM2 
indicated inactivating mutations in their study. p21, a tran-
scriptional target of p53, was considered to reflect p53 activity 
and could decrease false-positive results of p53 expression [28]. 
The ACRG considered a TP53-activity signature using p21 and 
MDM2 genes [7]. Therefore, in addition to p53 IHC, IHC for 
p21 and MDM2 would be helpful for evaluating the functional 
status of p53. The need for these additional analyses reflects a 
potential limitation of this study, necessitating further research.
In a total of 120 gastric cancer cases, 52 (43.3%) had TP53 
mutations, including nonsynonymous missense, frameshift, 
stop gain, in-frame deletion, and splice region mutations. Hot 
spot mutations within the central core (R175, G245, R248, 
R273, and R282) were observed in a minority of cases (10 out 
of 120 or 8.3%). In accordance with our results, a previous 
study reported hot spot mutations in 6.2% of gastric cancer 
cases [29]. Therefore, sequencing (Sanger or NGS) is suggested 
as a suitable method for detecting TP53 mutations in gastric 
cancer. 
In summary, we investigated the relationship between p53 
expression and TP53 mutation status to predict TP53 muta-
tions by p53 IHC and reveal their prognostic significance. TP53 
mutations were observed in 43.3% of cases. Strong p53 expres-
sion could predict nonsynonymous missense mutations with 
high sensitivity and specificity, but only half of the p53 negative 
cases (55.6%) exhibited other types of TP53 mutations. Protein 
overexpression and nonsynonymous genetic mutations of TP53 
significantly predicted worse OS. p53 IHC could be regarded as 
a simple surrogate marker of TP53 mutations, but negative ex-
pression of p53 and other types of TP53 mutations should be 
cautiously considered in daily practice or scientific research. Over-
all, our study results will be informative for simple molecular 
classification of patients with GC.
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